<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03865290</url>
  </required_header>
  <id_info>
    <org_study_id>18-005041</org_study_id>
    <secondary_id>P01DK068055</secondary_id>
    <nct_id>NCT03865290</nct_id>
  </id_info>
  <brief_title>Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia</brief_title>
  <official_title>Effects of Ondansetron on Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus and Dyspepsia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers are trying to understand why people with indigestion and diabetes mellitus have
      gastrointestinal symptoms and in particular to understand whether symptoms are related to
      increased sensitivity to nutrients in the small intestine. As part of this investigation, a
      medication called ondansetron will also be studied to determine its effects on
      gastrointestinal function and associated symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objectives of this study are to evaluate the effects of ondansetron, on symptoms
      (i) during a gastric emptying study, (ii) during enteral lipid infusion and (iii) in daily
      life.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2019</start_date>
  <completion_date type="Anticipated">March 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in severity of symptoms during enteral infusion</measure>
    <time_frame>baseline, every 15 minutes up to 8 hours</time_frame>
    <description>Visual analog scale (VAS) used to measure the change in symptom severity with a scale of 0=absent, 1=light, 2=moderate, 3=severe, 4=intolerable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity of symptoms during gastric emptying study</measure>
    <time_frame>baseline, every 15 minutes up to 2 hours</time_frame>
    <description>Visual analog scale (VAS) used to measure the change in symptom severity with a scale of 0=absent, 1=light, 2=moderate, 3=severe, 4=intolerable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity of daily symptoms</measure>
    <time_frame>Baseline, daily for six weeks</time_frame>
    <description>Gastroparesis Cardinal Symptom Index - Daily Diary (GCSI-DD) used to measure the change in symptoms severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity of gastrointestinal symptoms</measure>
    <time_frame>Baseline, 2 weeks, 6 weeks</time_frame>
    <description>Gastrointestinal Disorders - Symptom Severity Index (PAGI-SYM) used to measure the change in symptoms severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in severity of gastrointestinal symptoms effect on Quality of Life</measure>
    <time_frame>Baseline, 2 weeks, 6 weeks</time_frame>
    <description>Gastrointestinal Disorders - Quality of Life and Well-Being (PAGI-QOL) used to measure the change in symptoms severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in effect of Gastrointestinal symptoms on Quality of Life</measure>
    <time_frame>Baseline</time_frame>
    <description>Nepean Dyspepsia Index used to measure symptoms severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose level</measure>
    <time_frame>baseline, approximately 60-120 minutes</time_frame>
    <description>Compare the changes in glucose level during a lipid infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin level</measure>
    <time_frame>baseline, approximately 60-120 minutes</time_frame>
    <description>Compare the changes in insulin level during a lipid infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide level</measure>
    <time_frame>baseline, approximately 60-120 minutes</time_frame>
    <description>Compare the changes in C-peptide level during a lipid infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucagon-like Peptide 1 (GLP-1)</measure>
    <time_frame>baseline, approximately 60-120 minutes</time_frame>
    <description>Compare the changes in Glucagon-like Peptide 1 (GLP-1) level during a lipid infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholecystokinin (CCK)</measure>
    <time_frame>baseline, approximately 60-120 minutes</time_frame>
    <description>Compare the changes in Cholecystokinin (CCK) level during a lipid infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ghrelin</measure>
    <time_frame>baseline, approximately 60-120 minutes</time_frame>
    <description>Compare the changes in Ghrelin level during a lipid infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peptide YY (PYY)</measure>
    <time_frame>baseline, approximately 60-120 minutes</time_frame>
    <description>Compare the change in Peptide YY (PYY) level during a lipid infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma</measure>
    <time_frame>baseline, approximately 60-120 minutes</time_frame>
    <description>Compare the change in plasma level during a lipid infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of gastrointestinal symptoms on Quality of Life - Nepean Dyspepsia index</measure>
    <time_frame>Baseline</time_frame>
    <description>Score is derived from 25 items pertaining to QOL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of gastrointestinal symptoms - Nepean Dyspepsia index</measure>
    <time_frame>Baseline</time_frame>
    <description>Nepean Dyspepsia Index is used to measure symptom severity with a scale of 0=none, 1= very mild, 2=mild,3=moderate, 4=severe, 5= very severe</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Indigestion</condition>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Healthy Control Ondansetron 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic (DM) gastroenteropathy Ondansetron 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
Oral Ondansetron 8 mg administered three times a day for weeks 3-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ulcer dyspepsia (NUD) Ondansetron 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Ondansetron 8 mg administered in a single does dose during gastric emptying and duodenal infusion.
Oral Ondansetron 8 mg administered three times a day for weeks 3-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic (DM) gastroenteropathy Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
Oral matched placebo administered three times a day for weeks 3-6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ulcer dyspepsia (NUD) Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral matched placebo administered in a single does dose during gastric emptying and duodenal infusion.
Oral matched placebo administered three times a day for weeks 3-6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ondansetron 8mg</intervention_name>
    <description>Oral Ondansetron 8 mg</description>
    <arm_group_label>Diabetic (DM) gastroenteropathy Ondansetron 8 mg</arm_group_label>
    <arm_group_label>Healthy Control Ondansetron 8 mg</arm_group_label>
    <arm_group_label>Non-ulcer dyspepsia (NUD) Ondansetron 8 mg</arm_group_label>
    <other_name>Zofran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral matched placebo</description>
    <arm_group_label>Diabetic (DM) gastroenteropathy Placebo</arm_group_label>
    <arm_group_label>Healthy Control Placebo</arm_group_label>
    <arm_group_label>Non-ulcer dyspepsia (NUD) Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or non-pregnant, non-breastfeeding female volunteers;

          -  18-75 years old;

          -  Able to provide written informed consent before participating in the study

          -  Able to communicate adequately with the investigator and to comply with the
             requirements for the entire study; including the willingness and ability to consume
             the components of the test meals

          -  Symptoms of dyspepsia (i.e., early satiety, postprandial discomfort, nausea, vomiting,
             regurgitation)

          -  Patients in the DM group will also require Type 1 or 2 DM of â‰¥ 3 years duration; in
             patients with type 2 DM, the dyspepsia symptoms should have begun or worsened after DM
             was diagnosed

        Exclusion Criteria:

          -  Major abdominal surgery (i.e., appendectomy, cholecystectomy, tubal ligation,
             hysterectomy, herniorrhaphy, and limited colonic resection are permissible)

          -  Clinical evidence (including physical exam and EKG) of significant cardiovascular,
             respiratory, renal, hepatic, gastrointestinal, hematological, neurological,
             psychiatric or other disease that may interfere with the objectives of the study
             and/or pose safety concerns

          -  Current use of opiates, alpha adrenergic agonists, metoclopramide, monoamine oxidase
             inhibitors, more than one serotonergic medication, and high doses of anticholinergic
             agents (eg, amitriptyline greater than 50 mg daily). If medically safe, these drugs
             may be discontinued for four half lives prior to study assessments.

          -  Treatment with GLP-1 agonists and amlyin which cause vagal blockade and may affect
             central processing of pain

          -  Bleeding or clotting disorders or medications that increase risk of bleeding from
             mucosal biopsies

          -  Positive tissue transglutaminase antibodies (TTG),

          -  Pregnant or breast-feeding females

          -  Known intolerance or allergy to eggs

          -  Poor peripheral venous access, if central venous access is not available

          -  Any other condition or prior therapy that, in the opinion of the investigator, would
             make the patient unsuitable for the study

          -  History of Long QT Syndrome or prolonged QT interval (i.e., corrected QT interval &gt;
             480 ms)

          -  Current symptoms of a functional gastrointestinal disorder assessed by questionnaire

          -  Severe vomiting that would preclude tube placement or participation in the study

          -  Structural cause for symptoms by endoscopy within the past 12 months

          -  Patients with gastric pacemakers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adil E Bharucha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kelly J Feuerhak</last_name>
    <phone>507-255-6802</phone>
    <email>Feuerhak.Kelly@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly J Feuerhak</last_name>
      <phone>507-255-6802</phone>
      <email>Feuerhak.Kelly@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Adil E Bharucha, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>March 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2019</study_first_posted>
  <last_update_submitted>May 13, 2020</last_update_submitted>
  <last_update_submitted_qc>May 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Adil Bharucha, MBBS, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Dyspepsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ondansetron</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

